Boston-based PerkinElmer Life and Analytical Sciences has released the prOTOF™ 2000, the first commercially available matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass ...

Nail psoriasis is common in patients with plaque psoriasis and is associated with morbidity, including onychomycosis, which can complicate psoriasis treatments and be difficult to differentiate.

Perhaps no tool has been as instrumental to the proteomics revolution as the mass spectrometer. With the ability to deconvolute highly complex mixtures over a wide range of abundance levels, these ...

The webinar will give a current overview of label-free high-throughput MALDI TOF mass spectrometry and its use in drug discovery screening. It will explain the basics of MALDI TOF mass spectrometry ...

What is time-of-flight mass spectrometry? How ToF MS has gained more interest since the commercialization of MALDI. Why a high-speed ADC is key to ToF MS performance. Mixed-signal front end that ...

Scientific computing and the ability to write specific programs to analyze large datasets of biological information has become an increasingly important skill with regards to advancing biological ...

Collectively, the articles in the December 2017 special issue of SLAS Discovery on Advances in MALDI Mass Spectrometry within Drug Discovery present a snapshot of innovation in the MALDI application ...

neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam ...

The Chemistry Mass Spectrometry User Facility features a new Bruker AutofleX maX Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometer. This instrument allows for ...

Mass spectrometry has emerged as a transformative tool in microbial identification and characterisation, offering rapid, reliable and high-throughput analysis of complex biological samples. The ...

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT) ...